Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
31 Agosto 2022 - 6:00AM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the
“Company”), a clinical-stage biotechnology company developing
eganelisib, a first-in-class, oral, immuno-oncology macrophage
reprogramming therapeutic, today announced that the Company will
present and conduct 1-on-1 meetings with investors at the 2022
Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual
Global Investment Conference.
2022 Wells Fargo Healthcare Conference Date: Friday,
September 9, 2022 Time: 8:00 a.m. ET Speaker: Adelene Perkins,
Chief Executive Officer Format: In-person fireside chat and 1-on-1
meetings Webcast Registration Link
H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022 Time: Presentation available at
7:00 a.m. ET Speaker: Adelene Perkins, Chief Executive Officer
Format: Virtual company presentation and 1-on-1 meetings Webcast
Registration Link
A replay of the presentations will be available in the
Investors/Media section of Infinity's website at www.infi.com for
90 days following the events.
About Infinity and Eganelisib Infinity Pharmaceuticals,
Inc. (“Infinity” or the “Company”), is a clinical-stage
biotechnology company developing eganelisib (IPI-549), a
first-in-class, oral, immuno-oncology macrophage reprogramming
therapeutic which is designed to address a fundamental biologic
mechanism of immune suppression in cancer in multiple clinical
studies. MARIO-3 is the first eganelisib combination study in
front-line advanced cancer patients and is evaluating eganelisib in
combination with Tecentriq® and Abraxane® in front-line TNBC and in
combination with Tecentriq and Avastin® in front-line RCC.
MARIO-275 is a randomized, controlled combination study of
eganelisib combined with Opdivo® in I/O naïve urothelial cancer.
For more information on Infinity, please refer to Infinity's
website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane®
is a registered trademark of Abraxis BioScience, LLC., a wholly
owned subsidiary of Bristol Myers Squibb Company. Avastin® is a
registered trademark of Genentech, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220831005151/en/
Investor Relations: Kevin Lui Real Chemistry
klui@realchemistry.com
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024